Evaxion A/S Files May 2025 Report on Form 6-K

Ticker: EVAX · Form: 6-K · Filed: 2025-05-23T00:00:00.000Z

Sentiment: neutral

Topics: sec-filing, 6-k, foreign-private-issuer

Related Tickers: EVX

TL;DR

Evaxion A/S (EVX) filed its monthly 6-K, confirming 20-F annual report filings.

AI Summary

Evaxion A/S filed a Form 6-K on May 23, 2025, reporting its activities for the month of May 2025. The company, previously known as Evaxion Biotech A/S, is incorporated in G7 and has its principal executive offices in Hoersholm, Denmark. This filing is made under the Securities Exchange Act of 1934 and indicates that Evaxion A/S will file its annual reports under Form 20-F.

Why It Matters

This filing provides an update on Evaxion A/S's regulatory reporting status and confirms its adherence to SEC filing requirements for foreign private issuers.

Risk Assessment

Risk Level: low — This is a routine filing confirming reporting status and does not contain new financial or operational information.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to report information that the company has made or is required to make public in its home country, has filed or is required to file with a stock exchange, or has distributed or is required to distribute to its security holders.

What is the reporting period for this Form 6-K?

The filing is for the month of May 2025.

Does Evaxion A/S file annual reports under Form 20-F or Form 40-F?

Evaxion A/S indicates it files annual reports under cover of Form 20-F.

What was Evaxion A/S's former company name?

Evaxion A/S was formerly known as Evaxion Biotech A/S, with a date of name change on October 14, 2020.

Where are Evaxion A/S's principal executive offices located?

The principal executive offices of Evaxion A/S are located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

From the Filing

0001171843-25-003420.txt : 20250523 0001171843-25-003420.hdr.sgml : 20250523 20250523081521 ACCESSION NUMBER: 0001171843-25-003420 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250523 FILED AS OF DATE: 20250523 DATE AS OF CHANGE: 20250523 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25979332 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 BUSINESS PHONE: 4552656554 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM PROVINCE COUNTRY: G7 FORMER COMPANY: FORMER CONFORMED NAME: Evaxion Biotech A/S DATE OF NAME CHANGE: 20201014 6-K 1 f6k_052325.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39950 Evaxion A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On May 23, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled “Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025”. A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits   Exhibit No.   Description       99.1   Evaxion to announce business update and first quarter 2025 financial results on Ma

View on Read The Filing